Literature DB >> 6885896

Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.

M Sato, T Narisawa, M Sano, T Takahashi, A Goto.   

Abstract

The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38). Groups of BDF1 mice (C57BL/6 X DBA/2) were given intraperitoneal injections of this drug beginning on the 6th day after subcutaneous implantation of the tumor and continued for 4 to 8 days. In other groups of mice, identical treatment was delayed until the 16th day after implantation of the tumor. The higher antitumor activity against colon 38 was obtained with earlier initiation of treatment, indicated by decreased growth of the tumor and increased life span of the host. The later initiation of the treatment produced less antitumor activity. The antitumor activity was, however, less than that of 5-fluorouracil, which was used as a positive control drug. The two drugs in combination produced few advantages over 5-fluorouracil alone using the dose schedule designed in the present experiment. Indomethacin treatment significantly reduced prostaglandin E and F levels in the tumor tissue, but 5-fluorouracil did not. It seems likely that the inhibition of prostaglandin biosynthesis by indomethacin underlies the antitumor effect of this drug on colon 38.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6885896     DOI: 10.1007/bf00399893

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  The relationship between concentration of prostaglandin E and rates of cell replication.

Authors:  D R Thomas; G W Philpott; B M Jaffe
Journal:  Exp Cell Res       Date:  1974-03-15       Impact factor: 3.905

2.  Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse.

Authors:  V Hial; Z Horakova; F E Shaff; M A Beaven
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

3.  Macrophage-mediated tumor cell killing: regulation of expression of cytolytic activity by prostaglandin E.

Authors:  S M Taffet; S W Russell
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

4.  Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series.

Authors:  R M Schultz; N A Pavlidis; W A Stylos; M A Chirigos
Journal:  Science       Date:  1978-10-20       Impact factor: 47.728

5.  Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines.

Authors:  V Hial; M C De Mello; Z Horakova; M A Beaven
Journal:  J Pharmacol Exp Ther       Date:  1977-08       Impact factor: 4.030

6.  Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy.

Authors:  R D Maca; W R Panje
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

7.  Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin.

Authors:  B M Bayer; H S Kruth; M Vaughan; M A Beaven
Journal:  J Pharmacol Exp Ther       Date:  1979-07       Impact factor: 4.030

8.  Subversion of immune system by tumor cells and role of prostaglandins.

Authors:  O J Plescia; A H Smith; K Grinwich
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

9.  Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin.

Authors:  A M Fulton; J G Levy
Journal:  Int J Cancer       Date:  1980-11-15       Impact factor: 7.396

10.  Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy.

Authors:  A Bennett; D A Berstock; M A Carroll
Journal:  Br J Cancer       Date:  1982-05       Impact factor: 7.640

View more
  5 in total

1.  The marked anticancer effect of combined VCR, MTX, and indomethacin against drug-resistant recurrent small cell lung carcinoma after conventional chemotherapy: report of a case.

Authors:  S Kobayashi; S Okada; T Hasumi; N Sato; S Fujimura
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion.

Authors:  Micheline J Moussalli; Yuanqing Wu; Xiangsheng Zuo; Xiu L Yang; Ignacio Ivan Wistuba; Maria G Raso; Jeffrey S Morris; Jessica L Bowser; John D Minna; Reuben Lotan; Imad Shureiqi
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

3.  Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity.

Authors:  S Batkin; S J Taussig; J Szekerezes
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

4.  Effect of splenectomy on hepatic metastasis of colon carcinoma and natural killer activity in the liver.

Authors:  Y Shiratori; T Kawase; R Nakata; M Tanaka; Y Hikiba; K Okano; M Matsumura; Y Niwa; Y Komatsu; S Shiina
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

5.  Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues.

Authors:  M Ogino; H Hisatomi; M Murata; M Hanazono
Journal:  Jpn J Cancer Res       Date:  1999-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.